Objective: Various substances that can have an important effect on height a
re increasingly available. However, research into pharmacological manipulat
ion of height in children has been criticized. There are concerns about dia
gnostic criteria; about the medical, ethical, and economic ramifications of
modulating growth in children with no endocrinological abnormalities; and
about biased results due to weak study designs. The authors reviewed articl
es published since Jan. 1, 1995, to characterize recent research into this
area.
Methods: 70 peer-reviewed articles published in 18 journals in 1995 describ
ing effects of hormonal interventions to affect height were reviewed. Study
population, intervention, main purpose (safety, physiology, or therapeutic
effect), and methodology were examined. The search was expanded after 1995
to list randomized controlled trials (RCTs) investigating pharmacological
manipulation in children and its effect on ultimate height in adults.
Results: The inexpensive and brief androgen therapy for pubertal delay has
been examined in RCTs, but expensive, long-term treatments to alter final a
dult height in children have rarely been subjected to RCTs. Some outcome re
ports pooled subjects with different causes of short stature. Documentation
of growth hormone deficiency is problematic.
Conclusions: There is a lack of RCTs in which target populations and growth
outcomes are explicitly defined. Further research into overcoming barriers
to relevant RCT studies is needed.